A new non-viral DNA delivery vector: the terplex system
- PMID: 9741925
- DOI: 10.1016/s0168-3659(97)00251-4
A new non-viral DNA delivery vector: the terplex system
Abstract
A new DNA delivery vector (the terplex system) based on a balanced hydrophobicity and net surface charge between stearyl-poly(L-lysine), low density lipoprotein (LDL), and genetic material (i.e. plasmid DNA or antisense oligonucleotide) was developed. The pSV-beta-gal plasmid in terplex system showed a 2-5-fold increase in beta-galactosidase expression on murine smooth muscle cells (A7R5) compared to Lipofectin. Delivery of unmodified c-myb antisense oligonucleotide to A7R5 cells was also facilitated significantly by the terplex system, requiring as little as 5.4 nM of antisense oligonucleotide to achieve a 50% antiproliferative effect. Similar antiproliferative effect was observed when the c-myb antisense/terplex formulation was tested on CCD-32 Lu human lung fibroblasts. Characterization of the physical properties of the terplex system was performed using various techniques. Plasmid DNA was condensed by addition of stearyl-PLL and LDL, resulting in the terplex system of about 100 nm in diameter as shown by atomic force microscopy. A strong hydrophobic interaction between stearyl-poly(L-lysine) and LDL was registered by 1H-NMR spectrometry, showing a significant decrease in the epsilon-methylene signal of poly(L-lysine) backbone when stearyl-poly(L-lysine) was mixed with LDL; however, this phenomenon was not observed with unmodified poly(L-lysine). Agarose gel electrophoresis revealed that electrophoretic mobility of the terplex system decreased with increasing amounts of stearyl-poly(L-lysine), indicating that the surface charge of the terplex system became more positive by addition of stearyl-poly(L-lysine). Zeta-potential measurement showed that the terplex system exerted a slightly positive charge (+2 mV) at a 1:1:1 weight ratio of plasmid DNA:LDL:stearyl-poly(L-lysine). The obtained results will be utilized in the design of more efficient and safer DNA delivery vectors for in vivo gene therapy.
Similar articles
-
Terplex DNA delivery system as a gene carrier.Pharm Res. 1998 Jan;15(1):116-21. doi: 10.1023/a:1011917224044. Pharm Res. 1998. PMID: 9487557
-
Terplex gene delivery system.Adv Genet. 2005;53:263-74. Adv Genet. 2005. PMID: 16240997 Review.
-
Terplex Gene Delivery System.Adv Genet. 2005;53PA:263-274. doi: 10.1016/S0065-2660(05)53010-4. Adv Genet. 2005. PMID: 16243067
-
In vitro transfection with oligonucleotide DNA using polylysine copolymers.Cold Spring Harb Protoc. 2012 May 1;2012(5):pdb.prot068635. doi: 10.1101/pdb.prot068635. Cold Spring Harb Protoc. 2012. PMID: 22550290
-
Tailoring new gene delivery designs for specific targets.J Drug Target. 2000;8(1):1-12. doi: 10.3109/10611860009009205. J Drug Target. 2000. PMID: 10761641 Review.
Cited by
-
Recent advances in the development of gene delivery systems.Biomater Res. 2019 Mar 12;23:8. doi: 10.1186/s40824-019-0156-z. eCollection 2019. Biomater Res. 2019. PMID: 30915230 Free PMC article. Review.
-
Lipid-based drug carriers for prodrugs to enhance drug delivery.AAPS J. 2015 Jan;17(1):83-92. doi: 10.1208/s12248-014-9670-z. Epub 2014 Oct 1. AAPS J. 2015. PMID: 25269430 Free PMC article. Review.
-
Regulatable gene expression systems for gene therapy applications: progress and future challenges.Mol Ther. 2005 Aug;12(2):189-211. doi: 10.1016/j.ymthe.2005.03.022. Mol Ther. 2005. PMID: 15946903 Free PMC article. Review.
-
In vitro gene transfection in human glioma cells using a novel and less cytotoxic artificial lipoprotein delivery system.Pharm Res. 2003 May;20(5):738-44. doi: 10.1023/a:1023477317668. Pharm Res. 2003. PMID: 12751628
-
Regulatable gene expression systems for gene therapy.Curr Gene Ther. 2006 Aug;6(4):421-38. doi: 10.2174/156652306777934829. Curr Gene Ther. 2006. PMID: 16918333 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous